NCT03315689View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 14, 2017

Primary Completion Date

June 20, 2019

Study Completion Date

June 20, 2019

Conditions
Alopecia Universalis (AU)Alopecia Totalis (AT)
Interventions
DRUG

Vehicle

Vehicle Topical Solution

DRUG

ATI-50002

ATI-50002 Topical Solution

Trial Locations (2)

10032

Aclaris Investigational Site, New York

10075

Aclaris Investigational Site, New York

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY